董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lynn D. Bleil | 女 | Director | 57 | 37.80万美元 | 未持股 | 2021-04-27 |
| Craig Wheeler | 男 | Director | 60 | 29.30万美元 | 未持股 | 2021-04-27 |
| Burke W. Whitman | 男 | Director | 65 | 29.05万美元 | 未持股 | 2021-04-27 |
| John F. Crowley | 男 | Chairman and Chief Executive Officer | 54 | 1131.51万美元 | 未持股 | 2021-04-27 |
| Bradley L. Campbell | 男 | Director,President and Chief Operating Officer | 45 | 463.88万美元 | 未持股 | 2021-04-27 |
| Glenn P. Sblendorio | 男 | Director | 65 | 41.49万美元 | 未持股 | 2021-04-27 |
| Margaret G. McGlynn | 女 | Director | 61 | 39.89万美元 | 未持股 | 2021-04-27 |
| Michael A. Kelly | 男 | Director | 64 | 40.54万美元 | 未持股 | 2021-04-27 |
| Robert Essner | 男 | Director | 73 | 28.30万美元 | 未持股 | 2021-04-27 |
| Michael Raab | 男 | Director | 56 | 32.84万美元 | 未持股 | 2021-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ellen S. Rosenberg | 女 | Chief Legal Officer and Corporate Secretary | 58 | 288.58万美元 | 未持股 | 2021-04-27 |
| David M. Clark | 男 | Chief People Officer | 46 | 未披露 | 未持股 | 2021-04-27 |
| Samantha Prout | 女 | Vice President and Global Controller | 43 | 未披露 | 未持股 | 2021-04-27 |
| John F. Crowley | 男 | Chairman and Chief Executive Officer | 54 | 1131.51万美元 | 未持股 | 2021-04-27 |
| Bradley L. Campbell | 男 | Director,President and Chief Operating Officer | 45 | 463.88万美元 | 未持股 | 2021-04-27 |
| Daphne Quimi | 女 | Chief Financial Officer | 55 | 294.72万美元 | 未持股 | 2021-04-27 |
| Hung Do | 男 | Chief Science Officer | 53 | 277.21万美元 | 未持股 | 2021-04-27 |
董事简历
中英对照 | 中文 | 英文- Lynn D. Bleil
-
Lynn D. Bleil， 她一直担任董事（自2015年5月以来）。她曾担任McKinsey & Company的西海岸医疗实践领导人，以及McKinsey公司的全球医疗实践领导人。她于2013年11月退任McKinsey公司的南加州办公室的高级合伙人董事。任职McKinsey公司25年以上，她曾只从事医疗保健行业，并建议企业和业务单元战略、并购和整合、市场营销和销售、公共政策和组织的高级管理层和董事会。她也担任DST Systems, Inc.（金融和医疗服务信息技术公司）、Sonova Holding AG、Auspex Pharmaceuticals, Inc.（于2015年5月出售给Teva公司）的董事。她持有Princeton University的化学工程学士学位，以及斯坦福大学商学院 （ Stanford Graduate School of Business ）的工商管理硕士学位。
Lynn D. Bleil has served as a member of the Board since September 2018. Ms. Bleil led the West Coast Healthcare Practice of McKinsey & Company and was a core leader of McKinsey's worldwide Healthcare Practice before her retirement as a Senior Partner in 2013 after 25 years at the firm. Currently, Ms. Bleil serves as a member of the Board of Directors of Stericycle, Inc. NASDAQ: SRCL, Sonova Holding AG (VX: SOON) and Alcon AG (NYSE:ALC). Her prior directorships included DST Systems, Inc. (NYSE: DST), and Auspex Pharmaceuticals (NASDAQ: ASPX). Ms. Bleil received her B.S.E. in Chemical Engineering from Princeton University and her M.B.A. from the Stanford Graduate School of Business. - Lynn D. Bleil， 她一直担任董事（自2015年5月以来）。她曾担任McKinsey & Company的西海岸医疗实践领导人，以及McKinsey公司的全球医疗实践领导人。她于2013年11月退任McKinsey公司的南加州办公室的高级合伙人董事。任职McKinsey公司25年以上，她曾只从事医疗保健行业，并建议企业和业务单元战略、并购和整合、市场营销和销售、公共政策和组织的高级管理层和董事会。她也担任DST Systems, Inc.（金融和医疗服务信息技术公司）、Sonova Holding AG、Auspex Pharmaceuticals, Inc.（于2015年5月出售给Teva公司）的董事。她持有Princeton University的化学工程学士学位，以及斯坦福大学商学院 （ Stanford Graduate School of Business ）的工商管理硕士学位。
- Lynn D. Bleil has served as a member of the Board since September 2018. Ms. Bleil led the West Coast Healthcare Practice of McKinsey & Company and was a core leader of McKinsey's worldwide Healthcare Practice before her retirement as a Senior Partner in 2013 after 25 years at the firm. Currently, Ms. Bleil serves as a member of the Board of Directors of Stericycle, Inc. NASDAQ: SRCL, Sonova Holding AG (VX: SOON) and Alcon AG (NYSE:ALC). Her prior directorships included DST Systems, Inc. (NYSE: DST), and Auspex Pharmaceuticals (NASDAQ: ASPX). Ms. Bleil received her B.S.E. in Chemical Engineering from Princeton University and her M.B.A. from the Stanford Graduate School of Business.
- Craig Wheeler
-
Craig Wheeler自2016年6月起担任董事会成员。自2006年9月以来，Wheeler先生一直担任MomentaPharmaceuticals，Inc.总裁兼首席执行官纳斯达克股票代码:MNTA。在Momenta，Wheeler先生领导公司推出了第一个复杂的药物产品。他曾监管公司成长为今天的多元化业务。2011年，他是E&Y年度区域企业家奖获得者。2012年5月，《波士顿环球报》（Boston Globe）将Momenta评为年度全球100强表现公司调查中的第一名公司。加入Momenta公司之前，他曾担任Chiron Biopharmaceuticals公司的总裁，在那里他曾领导美国和欧洲商业组织，以及制药部门的全球销售2倍以上。在此之前，他是波士顿咨询集团（Boston Consulting Group）医疗保健实践的高级成员，并在医疗保健领域广泛工作，专注于制药和生物技术，特别是在企业和研发战略方面。他的职业生涯始于Merck&Company，Inc.（NYSE:MRK）的MSDRL研究单元。他此前也曾担任AvanirPharmaceuticals，Inc.的董事会主席，在那里他曾帮助监督该公司从基于研究的平台过渡到完全集成的CNS制药公司，直到2015年该公司被Otsuka Pharmaceuticals以35亿美元收购。Wheeler先生在康奈尔大学（Cornell University）获得化学工程学士学位和硕士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位。
Craig Wheeler has served as a member of the Board since June 2016. He is the CEO of Headwaters Biotech Advisors, where he serves as an advisor to executives in the Biotech industry. Mr. Wheeler recently completed a 14 year tenure as President and Chief Executive Officer of Momenta Pharmaceuticals NASDAQ: MNTA, where he grew the company from a startup, through multiple product launches, and ultimately to a $6.5B acquisition by J&J in the fall of 2020. In 2011 he was an E&Y Entrepreneur of the Year Regional Award winner. In May 2012 the Boston Globe named Momenta the number one company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr. Wheeler was President of Chiron Biopharmaceuticals where, during his five-year tenure, he led US and European commercial organizations and the pharmaceutical division's global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group's health care practice and worked extensively in the health care sector with focus on pharma and biotech, particularly in regard to corporate and R&D strategy. He began his career at Merck & Company, Inc.'s (NYSE: MRK) MSDRL research unit. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals, Inc. where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. Mr. Wheeler received his B.S. and M.S. in chemical engineering from Cornell University and his M.B.A. from the Wharton School of the University of Pennsylvania. - Craig Wheeler自2016年6月起担任董事会成员。自2006年9月以来，Wheeler先生一直担任MomentaPharmaceuticals，Inc.总裁兼首席执行官纳斯达克股票代码:MNTA。在Momenta，Wheeler先生领导公司推出了第一个复杂的药物产品。他曾监管公司成长为今天的多元化业务。2011年，他是E&Y年度区域企业家奖获得者。2012年5月，《波士顿环球报》（Boston Globe）将Momenta评为年度全球100强表现公司调查中的第一名公司。加入Momenta公司之前，他曾担任Chiron Biopharmaceuticals公司的总裁，在那里他曾领导美国和欧洲商业组织，以及制药部门的全球销售2倍以上。在此之前，他是波士顿咨询集团（Boston Consulting Group）医疗保健实践的高级成员，并在医疗保健领域广泛工作，专注于制药和生物技术，特别是在企业和研发战略方面。他的职业生涯始于Merck&Company，Inc.（NYSE:MRK）的MSDRL研究单元。他此前也曾担任AvanirPharmaceuticals，Inc.的董事会主席，在那里他曾帮助监督该公司从基于研究的平台过渡到完全集成的CNS制药公司，直到2015年该公司被Otsuka Pharmaceuticals以35亿美元收购。Wheeler先生在康奈尔大学（Cornell University）获得化学工程学士学位和硕士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位。
- Craig Wheeler has served as a member of the Board since June 2016. He is the CEO of Headwaters Biotech Advisors, where he serves as an advisor to executives in the Biotech industry. Mr. Wheeler recently completed a 14 year tenure as President and Chief Executive Officer of Momenta Pharmaceuticals NASDAQ: MNTA, where he grew the company from a startup, through multiple product launches, and ultimately to a $6.5B acquisition by J&J in the fall of 2020. In 2011 he was an E&Y Entrepreneur of the Year Regional Award winner. In May 2012 the Boston Globe named Momenta the number one company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr. Wheeler was President of Chiron Biopharmaceuticals where, during his five-year tenure, he led US and European commercial organizations and the pharmaceutical division's global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group's health care practice and worked extensively in the health care sector with focus on pharma and biotech, particularly in regard to corporate and R&D strategy. He began his career at Merck & Company, Inc.'s (NYSE: MRK) MSDRL research unit. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals, Inc. where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. Mr. Wheeler received his B.S. and M.S. in chemical engineering from Cornell University and his M.B.A. from the Wharton School of the University of Pennsylvania.
- Burke W. Whitman
-
Burke W. Whitman自2019年6月起担任董事会成员。他还担任Omega 医疗保健投资者纽约证券交易所代码：OHI的董事会成员；海军陆战队传统基金会董事会；洛维特学校董事会；预备役部队政策委员会；以及私人投资公司Colmar Holdings的首席执行官。此前，他曾于2005-08年担任Health Management Associates（纽约证券交易所代码：医疗保健）的首席执行官（最初是首席运营官）；1998-2005年担任Triad Hospitals（纽约证券交易所代码：TRI）的副总裁；1994-98年担任Deerfield Hospitals（私营）的总裁；1992-94年担任Almost Family（纳斯达克市场代码：AFAM）的副总裁1；1988-92年担任摩根士丹利的投资银行家。2018年，他先后担任美国海军陆战队预备役Major General和高级预备役军官，服务了33年，其中包括1985-1988年和2009-18年期间的现役，当时他在国防部长手下服役，领导了多个部署，曾任海军陆战队预备役司令和第4陆战师司令。惠特曼先生曾在美国医院联合会董事会（审计主席）、玩具基金会董事会（投资主席）、海军陆战队大学游客委员会和海军陆战队国家博物馆创始人小组任职。他拥有哈佛商学院的MBA学位、陆军战争学院的战略研究硕士学位和达特茅斯学院的学士学位。
Burke W. Whitman has served as a member of the Board since June 2019. He also serves as a member of the Board of Directors of Omega Healthcare Investors NYSE: OHI; Board of Directors of the Marine Corps Heritage Foundation; Board of Trustees of The Lovett School; Reserve Forces Policy Board; and as Chief Executive of Colmar Holdings, a private investment company. Previously he served as Chief Executive Officer (and initially Chief Operating Officer) of Health Management Associates (NYSE: HMA) 2005-08; Chief Financial Officer of Triad Hospitals (NYSE: TRI) 1998-2005; President of Deerfield Healthcare (private) 1994-98; Vice President of Almost Family (Nasdaq: AFAM) 1992-94; and Investment Banker with Morgan Stanley (NYSE: MS) 1988-92. Concurrently through 2018 he served as a reserve Major General and the senior reserve officer of the United States Marine Corps, capping 33 years of service which included active duty during 1985-88 and 2009-18 when he served with the Secretary of Defense, led multiple deployments, and was Commanding General of Marine Forces Reserve and the 4th Marine Division. Mr. Whitman previously served on the Board of Directors of the Federation of American Hospitals (Audit Chair), Board of Directors of the Toys for Tots Foundation (Investment Chair), Board of Visitors of Marine Corps University, and Founders Group of the National Museum of the Marine Corps. He holds an MBA from Harvard Business School, a Master of Strategic Studies from the Army War College, and a BA from Dartmouth College. - Burke W. Whitman自2019年6月起担任董事会成员。他还担任Omega 医疗保健投资者纽约证券交易所代码：OHI的董事会成员；海军陆战队传统基金会董事会；洛维特学校董事会；预备役部队政策委员会；以及私人投资公司Colmar Holdings的首席执行官。此前，他曾于2005-08年担任Health Management Associates（纽约证券交易所代码：医疗保健）的首席执行官（最初是首席运营官）；1998-2005年担任Triad Hospitals（纽约证券交易所代码：TRI）的副总裁；1994-98年担任Deerfield Hospitals（私营）的总裁；1992-94年担任Almost Family（纳斯达克市场代码：AFAM）的副总裁1；1988-92年担任摩根士丹利的投资银行家。2018年，他先后担任美国海军陆战队预备役Major General和高级预备役军官，服务了33年，其中包括1985-1988年和2009-18年期间的现役，当时他在国防部长手下服役，领导了多个部署，曾任海军陆战队预备役司令和第4陆战师司令。惠特曼先生曾在美国医院联合会董事会（审计主席）、玩具基金会董事会（投资主席）、海军陆战队大学游客委员会和海军陆战队国家博物馆创始人小组任职。他拥有哈佛商学院的MBA学位、陆军战争学院的战略研究硕士学位和达特茅斯学院的学士学位。
- Burke W. Whitman has served as a member of the Board since June 2019. He also serves as a member of the Board of Directors of Omega Healthcare Investors NYSE: OHI; Board of Directors of the Marine Corps Heritage Foundation; Board of Trustees of The Lovett School; Reserve Forces Policy Board; and as Chief Executive of Colmar Holdings, a private investment company. Previously he served as Chief Executive Officer (and initially Chief Operating Officer) of Health Management Associates (NYSE: HMA) 2005-08; Chief Financial Officer of Triad Hospitals (NYSE: TRI) 1998-2005; President of Deerfield Healthcare (private) 1994-98; Vice President of Almost Family (Nasdaq: AFAM) 1992-94; and Investment Banker with Morgan Stanley (NYSE: MS) 1988-92. Concurrently through 2018 he served as a reserve Major General and the senior reserve officer of the United States Marine Corps, capping 33 years of service which included active duty during 1985-88 and 2009-18 when he served with the Secretary of Defense, led multiple deployments, and was Commanding General of Marine Forces Reserve and the 4th Marine Division. Mr. Whitman previously served on the Board of Directors of the Federation of American Hospitals (Audit Chair), Board of Directors of the Toys for Tots Foundation (Investment Chair), Board of Visitors of Marine Corps University, and Founders Group of the National Museum of the Marine Corps. He holds an MBA from Harvard Business School, a Master of Strategic Studies from the Army War College, and a BA from Dartmouth College.
- John F. Crowley
-
John F. Crowley，自2010年2月他为董事长兼首席执行官，自2005年1月起为首席执行官，除了从2011年4月至2011年8月期间出任执行董事长。自2004年8月，他还担任Amicus的董事，除了从2006年9月至2007年3月的期间时，他不是Amicus的职员或董事，而是在美国的海军预备役部队服役。他是Orexigen Therapeutics的总裁兼首席执行官从2003年9月至2004年12月。他Novazyme制药公司的总裁兼首席执行官从2000年3月，直到该公司于2001年9月被Genzyme公司收购；此后，他曾担任 Genzyme Therapeutics的高级副总裁直至2002年12月。他获得乔治城大学的外交学院的外交服务学士学位，圣母大学法学院的法学博士学位，和哈佛商学院的MBA学位。
John F. Crowley has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January 2005 except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr. Crowley has also served as a director of Amicus since August 2004 except for the period from September 2006 to March 2007 when he was in active duty service in the United States Navy Reserve. Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporation (“Genzyme”) in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Currently, Mr. Crowley serves as a member of the Board of Directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Mr. Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School. - John F. Crowley，自2010年2月他为董事长兼首席执行官，自2005年1月起为首席执行官，除了从2011年4月至2011年8月期间出任执行董事长。自2004年8月，他还担任Amicus的董事，除了从2006年9月至2007年3月的期间时，他不是Amicus的职员或董事，而是在美国的海军预备役部队服役。他是Orexigen Therapeutics的总裁兼首席执行官从2003年9月至2004年12月。他Novazyme制药公司的总裁兼首席执行官从2000年3月，直到该公司于2001年9月被Genzyme公司收购；此后，他曾担任 Genzyme Therapeutics的高级副总裁直至2002年12月。他获得乔治城大学的外交学院的外交服务学士学位，圣母大学法学院的法学博士学位，和哈佛商学院的MBA学位。
- John F. Crowley has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January 2005 except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr. Crowley has also served as a director of Amicus since August 2004 except for the period from September 2006 to March 2007 when he was in active duty service in the United States Navy Reserve. Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporation (“Genzyme”) in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Currently, Mr. Crowley serves as a member of the Board of Directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Mr. Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School.
- Bradley L. Campbell
-
Bradley L. Campbell，自2013年12月，他曾担任首席运营官，自2012年2月为首席商务官。2010年1月至2012年2月他担任业务运营高级副总裁；从2007年5月至2010年1月担任业务规划副总裁，并从2006年4月至2007年5月为业务发展高级总监。他担任Myozyme的庞贝氏症的高级产品经理，后来从2002年至2006年担任Genzyme公司的心血管基因治疗业务总监。他还曾在 Bristol-Myers Squibb的销售和市场营销部门工作，并为 Marakon Associates的企业战略顾问。他获得杜克大学的学士学位和哈佛商学院工商管理硕士学位。
Bradley L. Campbell has served as a member of the Board since June 2018 and as President and Chief Operating Officer since January 2015. Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012 Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010 as Vice President, Business Planning and from April 2006 until May 2007 as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme©- for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for Bristol Myers Squibb and as a business strategy consultant for Marakon Associates. Currently, Mr. Campbell also serves as a director for ARYA Sciences Acquisitions Corp III NASDAQ: ARYA and previously served as a director of Progenics (NASDAQ: PGNX). Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School. - Bradley L. Campbell，自2013年12月，他曾担任首席运营官，自2012年2月为首席商务官。2010年1月至2012年2月他担任业务运营高级副总裁；从2007年5月至2010年1月担任业务规划副总裁，并从2006年4月至2007年5月为业务发展高级总监。他担任Myozyme的庞贝氏症的高级产品经理，后来从2002年至2006年担任Genzyme公司的心血管基因治疗业务总监。他还曾在 Bristol-Myers Squibb的销售和市场营销部门工作，并为 Marakon Associates的企业战略顾问。他获得杜克大学的学士学位和哈佛商学院工商管理硕士学位。
- Bradley L. Campbell has served as a member of the Board since June 2018 and as President and Chief Operating Officer since January 2015. Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012 Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010 as Vice President, Business Planning and from April 2006 until May 2007 as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme©- for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for Bristol Myers Squibb and as a business strategy consultant for Marakon Associates. Currently, Mr. Campbell also serves as a director for ARYA Sciences Acquisitions Corp III NASDAQ: ARYA and previously served as a director of Progenics (NASDAQ: PGNX). Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School.
- Glenn P. Sblendorio
-
Glenn P. Sblendorio自2006年6月起担任Amicus Therapeutics, Inc.的董事会成员。他目前是IVERIC bio, Inc.的首席执行官。NASDAQ: ISEE，前身为Ophthotech Corporation (NASDAQ: OPHT)，他自2017年以来一直担任该职位，并且是IVERIC的董事会成员。加入IVERIC之前，他从2006年3月到2016年3月担任The Medicines Company (NASDAQ: MDCO)的总裁兼首席财务官，并从2011年7月到2015年12月31日担任The Medicines Company的董事会成员。加入The Medicines Company之前，他从2002年2月起担任Eyetech Pharmaceuticals, Inc.的执行副总裁兼首席财务官，直到该公司于2005年11月被OSI Pharmaceuticals, Inc.收购。他还担任Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)的董事会成员(审计主席)。他持有Pace University的工商管理硕士学位和Fairleigh Dickinson University的工商管理硕士学位。
Glenn P. Sblendorio has served as a member of the Board of Amicus Therapeutics, Inc. since June 2006. Mr. Sblendorio is currently Chief Executive Officer of IVERIC bio, Inc. NASDAQ: ISEE, formerly Ophthotech Corporation (NASDAQ: OPHT), a position that he has held since 2017 and is a member of the Board of Directors of IVERIC. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company (NASDAQ: MDCO) from March 2006 through March 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also serves as a member of the Board of Directors of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Chair, Audit). Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University. - Glenn P. Sblendorio自2006年6月起担任Amicus Therapeutics, Inc.的董事会成员。他目前是IVERIC bio, Inc.的首席执行官。NASDAQ: ISEE，前身为Ophthotech Corporation (NASDAQ: OPHT)，他自2017年以来一直担任该职位，并且是IVERIC的董事会成员。加入IVERIC之前，他从2006年3月到2016年3月担任The Medicines Company (NASDAQ: MDCO)的总裁兼首席财务官，并从2011年7月到2015年12月31日担任The Medicines Company的董事会成员。加入The Medicines Company之前，他从2002年2月起担任Eyetech Pharmaceuticals, Inc.的执行副总裁兼首席财务官，直到该公司于2005年11月被OSI Pharmaceuticals, Inc.收购。他还担任Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)的董事会成员(审计主席)。他持有Pace University的工商管理硕士学位和Fairleigh Dickinson University的工商管理硕士学位。
- Glenn P. Sblendorio has served as a member of the Board of Amicus Therapeutics, Inc. since June 2006. Mr. Sblendorio is currently Chief Executive Officer of IVERIC bio, Inc. NASDAQ: ISEE, formerly Ophthotech Corporation (NASDAQ: OPHT), a position that he has held since 2017 and is a member of the Board of Directors of IVERIC. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company (NASDAQ: MDCO) from March 2006 through March 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also serves as a member of the Board of Directors of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Chair, Audit). Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University.
- Margaret G. McGlynn
-
Margaret G. McGlynn， 自2011年7月以来，她一直担任国际艾滋病疫苗倡议的总裁兼首席执行官，该组织是一个全球非营利组织，其宗旨是确保HIV疫苗在整个世界能被安全，有效，方便得开发利用。她自从2005年到2009年一直致力于疫苗和传染病研究的美国默克制药公司。她于1983年加入默克制药公司，在各种市场营销，销售和服务管理式医疗扮演多个角色。目前，她是空气产品和化学品公司董事会的一员，该公司专门从事工业实用的气体和化学品。她同样也是一家生物制药公司— Amicus Therapeutics公司董事会的一员。她是全国工业咨询委员会在大学药学和制药科学布法罗学院的一员。麦格林女士持有药学学士学位和市场营销学硕士学位，并获纽约州立大学水牛城分校荣誉博士学位。
Margaret G. McGlynn Retired from Merck & Co. in 2009 where she served as President, Vaccines and Infectious Diseases and as President, Hospital and Specialty Products.Held various leadership roles in the U.S. and globally in marketing, sales, managed care, and business development during her 26-year career at Merck.President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015.Member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.Member of the Board of Directors of Air Products and Chemicals, Inc., a publicly traded company specializing in gases and chemicals for industrial uses, from 2005 to November 2020.Holds a B.S. in Pharmacy, an M.B.A. in Marketing, and an Honorary Doctorate from the State University of New York at Buffalo. - Margaret G. McGlynn， 自2011年7月以来，她一直担任国际艾滋病疫苗倡议的总裁兼首席执行官，该组织是一个全球非营利组织，其宗旨是确保HIV疫苗在整个世界能被安全，有效，方便得开发利用。她自从2005年到2009年一直致力于疫苗和传染病研究的美国默克制药公司。她于1983年加入默克制药公司，在各种市场营销，销售和服务管理式医疗扮演多个角色。目前，她是空气产品和化学品公司董事会的一员，该公司专门从事工业实用的气体和化学品。她同样也是一家生物制药公司— Amicus Therapeutics公司董事会的一员。她是全国工业咨询委员会在大学药学和制药科学布法罗学院的一员。麦格林女士持有药学学士学位和市场营销学硕士学位，并获纽约州立大学水牛城分校荣誉博士学位。
- Margaret G. McGlynn Retired from Merck & Co. in 2009 where she served as President, Vaccines and Infectious Diseases and as President, Hospital and Specialty Products.Held various leadership roles in the U.S. and globally in marketing, sales, managed care, and business development during her 26-year career at Merck.President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015.Member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.Member of the Board of Directors of Air Products and Chemicals, Inc., a publicly traded company specializing in gases and chemicals for industrial uses, from 2005 to November 2020.Holds a B.S. in Pharmacy, an M.B.A. in Marketing, and an Honorary Doctorate from the State University of New York at Buffalo.
- Michael A. Kelly
-
Michael A. Kelly， 自2008年7月起出任董事，并担任薪酬委员会委员。自2012年10月他担任3M公司电子和能源业务执行副总裁，之前自2006年10月他曾任该公司显示与图形执行副总裁。在此之前，自从他在1981年加入了3M，他曾在美国，新加坡韩国和德国担任多个管理职位。他曾在宾夕法尼亚大学沃顿商学院读完了行政教育。在他担任3M公司的电子和能源业务的执行副总裁期间，他要负责这价值60亿的全球业务所有运营和策略工作，包括3M的电子材料，电气市场，通信市场，电子解决方案，可再生能源，以及光学系统业务。
Michael A. Kelly,Retired Executive Vice President, Electronics and Energy Business of 3M Company, a diversified global technology company, from 2012 to 2016; he also served as Executive Vice President of the Display and Graphic Business from 2006 to 2012, and in various management positions in the U.S., Singapore, Korea and Germany. - Michael A. Kelly， 自2008年7月起出任董事，并担任薪酬委员会委员。自2012年10月他担任3M公司电子和能源业务执行副总裁，之前自2006年10月他曾任该公司显示与图形执行副总裁。在此之前，自从他在1981年加入了3M，他曾在美国，新加坡韩国和德国担任多个管理职位。他曾在宾夕法尼亚大学沃顿商学院读完了行政教育。在他担任3M公司的电子和能源业务的执行副总裁期间，他要负责这价值60亿的全球业务所有运营和策略工作，包括3M的电子材料，电气市场，通信市场，电子解决方案，可再生能源，以及光学系统业务。
- Michael A. Kelly,Retired Executive Vice President, Electronics and Energy Business of 3M Company, a diversified global technology company, from 2012 to 2016; he also served as Executive Vice President of the Display and Graphic Business from 2006 to 2012, and in various management positions in the U.S., Singapore, Korea and Germany.
- Robert Essner
-
Robert Essner，是Wyeth Pharmaceuticals, Inc.的前任董事长、首席执行官兼总裁，惠氏制药公司是一家全球性制药公司，该公司现在是辉瑞公司的一部分。具体来说，他在2003年至2008年从惠氏退休期间担任惠氏董事长，在2001年至2007年期间担任其首席执行官，在2000年至2006年期间担任其总裁，在2000年至2001年期间担任其首席运营官，在1997年至2000年期间担任其执行副总裁。在加入惠氏之前，Essner先生曾在Sandoz Pharmaceuticals Corporation担任过十多年的多个高级管理职位，此外还曾在2009年至2019年期间担任私募股权、另类资产管理和金融服务公司The Carlyle Group Inc. Global Healthcare的高级顾问。他还担任哥伦比亚商学院的常驻高管和商学兼职教授，在那里他教授医疗保健管理课程，此前曾担任爱美医疗公司的董事。Essner先生毕业于迈阿密大学，获得芝加哥大学硕士学位。
Robert Essner,is the former Chairman, Chief Executive Officer and President of Wyeth Pharmaceuticals, Inc., a global pharmaceuticals company, which is now part of Pfizer Inc. Specifically, he served as Wyeth's Chairman between 2003 and his retirement from Wyeth in 2008, as its Chief Executive Officer between 2001 and 2007, its President between 2000 and 2006, its Chief Operating Officer between 2000 and 2001 and its Executive Vice President between 1997 and 2000. Prior to Wyeth, Mr. Essner spent more than a decade in various senior management positions at Sandoz Pharmaceuticals Corporation, in addition to serving as a Senior Advisor of Global Healthcare for The Carlyle Group Inc., a private equity, alternative asset management and financial services corporation, between 2009 and 2019. He also serves as an Executive in Residence and Adjunct Professor of Business at Columbia Business School, where he teaches courses in healthcare management, and previously served as a director of Amicus Therapeutics Inc. Mr. Essner is a graduate of Miami University and received his master's degree from the University of Chicago. - Robert Essner，是Wyeth Pharmaceuticals, Inc.的前任董事长、首席执行官兼总裁，惠氏制药公司是一家全球性制药公司，该公司现在是辉瑞公司的一部分。具体来说，他在2003年至2008年从惠氏退休期间担任惠氏董事长，在2001年至2007年期间担任其首席执行官，在2000年至2006年期间担任其总裁，在2000年至2001年期间担任其首席运营官，在1997年至2000年期间担任其执行副总裁。在加入惠氏之前，Essner先生曾在Sandoz Pharmaceuticals Corporation担任过十多年的多个高级管理职位，此外还曾在2009年至2019年期间担任私募股权、另类资产管理和金融服务公司The Carlyle Group Inc. Global Healthcare的高级顾问。他还担任哥伦比亚商学院的常驻高管和商学兼职教授，在那里他教授医疗保健管理课程，此前曾担任爱美医疗公司的董事。Essner先生毕业于迈阿密大学，获得芝加哥大学硕士学位。
- Robert Essner,is the former Chairman, Chief Executive Officer and President of Wyeth Pharmaceuticals, Inc., a global pharmaceuticals company, which is now part of Pfizer Inc. Specifically, he served as Wyeth's Chairman between 2003 and his retirement from Wyeth in 2008, as its Chief Executive Officer between 2001 and 2007, its President between 2000 and 2006, its Chief Operating Officer between 2000 and 2001 and its Executive Vice President between 1997 and 2000. Prior to Wyeth, Mr. Essner spent more than a decade in various senior management positions at Sandoz Pharmaceuticals Corporation, in addition to serving as a Senior Advisor of Global Healthcare for The Carlyle Group Inc., a private equity, alternative asset management and financial services corporation, between 2009 and 2019. He also serves as an Executive in Residence and Adjunct Professor of Business at Columbia Business School, where he teaches courses in healthcare management, and previously served as a director of Amicus Therapeutics Inc. Mr. Essner is a graduate of Miami University and received his master's degree from the University of Chicago.
- Michael Raab
-
自2009年3月，Michael Raab担任Amicus Therapeutics, Inc.的总裁、首席执行官和董事。从2002年到2009年，他担任New Enterprise Associates, or NEA合伙人，一家风险投资公司，专门从事生物技术和制药行的医疗投资业。加入NEA之前，他在生物技术和制药行业担任商业和运营领导职务15年。他担任Genzyme Corporation治疗高级副总裁和Renal部门总经理，一家生物技术公司。他在Genzyme任职2年，在诊断产品和服务部门工作。加入Genzyme之前，他担任Repligen公司业务开发、销售和营销职务，一家生命科学公司和Bristol-Myers Squibb公司，一家生物制药公司。他拥有迪堡大学学士学位。
Michael Raab,has served as President and Chief Executive Officer since March 2009 and as a director since 2008. From 2002 to 2009, Mr. Raab was a partner at NEA, an investment firm focused on venture capital and growth equity investments, where he focused on investments in the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries, including serving as Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, or Genzyme, a biotechnology company. Mr. Raab also spent two years with Genzyme's diagnostic products and services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporation, a life sciences company, and Bristol-Myers Corporation. Mr. Raab is currently the lead independent director of Amicus Therapeutics, Inc. (Nasdaq: FOLD) and also serves as the chairperson of the board of directors of Tempest Therapeutics (Nasdaq CM: TPST). Mr. Raab also currently serves as a member of the Emerging Companies Section Governing Board and the Health Section Governing Board of the Biotechnology Innovation Organization. Mr. Raab received a B.A. from DePauw University. - 自2009年3月，Michael Raab担任Amicus Therapeutics, Inc.的总裁、首席执行官和董事。从2002年到2009年，他担任New Enterprise Associates, or NEA合伙人，一家风险投资公司，专门从事生物技术和制药行的医疗投资业。加入NEA之前，他在生物技术和制药行业担任商业和运营领导职务15年。他担任Genzyme Corporation治疗高级副总裁和Renal部门总经理，一家生物技术公司。他在Genzyme任职2年，在诊断产品和服务部门工作。加入Genzyme之前，他担任Repligen公司业务开发、销售和营销职务，一家生命科学公司和Bristol-Myers Squibb公司，一家生物制药公司。他拥有迪堡大学学士学位。
- Michael Raab,has served as President and Chief Executive Officer since March 2009 and as a director since 2008. From 2002 to 2009, Mr. Raab was a partner at NEA, an investment firm focused on venture capital and growth equity investments, where he focused on investments in the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries, including serving as Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, or Genzyme, a biotechnology company. Mr. Raab also spent two years with Genzyme's diagnostic products and services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporation, a life sciences company, and Bristol-Myers Corporation. Mr. Raab is currently the lead independent director of Amicus Therapeutics, Inc. (Nasdaq: FOLD) and also serves as the chairperson of the board of directors of Tempest Therapeutics (Nasdaq CM: TPST). Mr. Raab also currently serves as a member of the Emerging Companies Section Governing Board and the Health Section Governing Board of the Biotechnology Innovation Organization. Mr. Raab received a B.A. from DePauw University.
高管简历
中英对照 | 中文 | 英文- Ellen S. Rosenberg
EllenS.Rosenberg，自2016年2月起担任我们的总法律顾问兼公司秘书。加入Amicus公司之前，她曾担任Shire Pharmaceuticals公司的高级副总裁，副总法律顾问。任职Shire公司之前，Rosenberg曾担任EMD Serono Inc.（Merck KGaA公司的美国附属公司）的代谢内分泌部门的副总法律顾问。Rosenberg在University of Connecticut获得B.A.，在University of Pennsylvania Law School获得J.D.。
Ellen S. Rosenberg, has served as our Chief Legal Officer and Corporate Secretary since December 2018 and our General Counsel and Corporate Secretary since February 2016. Prior to joining Amicus, she served as a Senior Vice President of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA. Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Carey Law School.- EllenS.Rosenberg，自2016年2月起担任我们的总法律顾问兼公司秘书。加入Amicus公司之前，她曾担任Shire Pharmaceuticals公司的高级副总裁，副总法律顾问。任职Shire公司之前，Rosenberg曾担任EMD Serono Inc.（Merck KGaA公司的美国附属公司）的代谢内分泌部门的副总法律顾问。Rosenberg在University of Connecticut获得B.A.，在University of Pennsylvania Law School获得J.D.。
- Ellen S. Rosenberg, has served as our Chief Legal Officer and Corporate Secretary since December 2018 and our General Counsel and Corporate Secretary since February 2016. Prior to joining Amicus, she served as a Senior Vice President of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA. Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Carey Law School.
- David M. Clark
David M. Clark自2018年10月起担任我们的首席人力官。克拉克先生曾于2016年9月至2018年8月在总部位于中国杭州的阿里巴巴集团担任全球人力资源副总裁。在此之前，克拉克先生在美国运通公司工作了8年，担任人力资源高级副总裁兼首席学习官。在此期间，克拉克先生是人力资源业务的高级合伙人，并领导了学习、领导力发展和绩效管理的变革。在此之前，克拉克先生是白宫高级幕僚的委任官员。作为美国总统的副助理，他领导了美国政府4000名最高级别领导人的招聘和发展工作。克拉克先生获得印第安纳州立大学政治学学士学位。他是一名老鹰童军，并在美国童军的国家执行委员会任职。克拉克先生还是美国许愿基金会的名誉主席。
David M. Clark, has served as our Chief People Officer since October 2018. Mr. Clark was previously Vice President of Global Human Resources HR at Alibaba Group, headquartered in Hangzhou, China, from September 2016 to August 2018. Prior to that, Mr. Clark spent eight years at American Express, where he was Senior Vice President of Human Resources and Chief Learning Officer. While there, Mr. Clark was a senior HR Business Partner and led the transformation of learning, leadership development and performance management. Previously, Mr. Clark was a Commissioned Officer on the White House senior staff. As Deputy Assistant to the President of the United States, he led the recruitment and development of the 4000 most senior leaders in the U.S. government. Mr. Clark received a B.S. in political science from Indiana State University. He is an Eagle Scout and serves on the National Executive Board of the Boy Scouts of America. Mr. Clark is also the Chairman-Emeritus of the Board of the Make-A-Wish Foundation of America.- David M. Clark自2018年10月起担任我们的首席人力官。克拉克先生曾于2016年9月至2018年8月在总部位于中国杭州的阿里巴巴集团担任全球人力资源副总裁。在此之前，克拉克先生在美国运通公司工作了8年，担任人力资源高级副总裁兼首席学习官。在此期间，克拉克先生是人力资源业务的高级合伙人，并领导了学习、领导力发展和绩效管理的变革。在此之前，克拉克先生是白宫高级幕僚的委任官员。作为美国总统的副助理，他领导了美国政府4000名最高级别领导人的招聘和发展工作。克拉克先生获得印第安纳州立大学政治学学士学位。他是一名老鹰童军，并在美国童军的国家执行委员会任职。克拉克先生还是美国许愿基金会的名誉主席。
- David M. Clark, has served as our Chief People Officer since October 2018. Mr. Clark was previously Vice President of Global Human Resources HR at Alibaba Group, headquartered in Hangzhou, China, from September 2016 to August 2018. Prior to that, Mr. Clark spent eight years at American Express, where he was Senior Vice President of Human Resources and Chief Learning Officer. While there, Mr. Clark was a senior HR Business Partner and led the transformation of learning, leadership development and performance management. Previously, Mr. Clark was a Commissioned Officer on the White House senior staff. As Deputy Assistant to the President of the United States, he led the recruitment and development of the 4000 most senior leaders in the U.S. government. Mr. Clark received a B.S. in political science from Indiana State University. He is an Eagle Scout and serves on the National Executive Board of the Boy Scouts of America. Mr. Clark is also the Chairman-Emeritus of the Board of the Make-A-Wish Foundation of America.
- Samantha Prout
Samantha Prout自2020年3月起担任副总裁兼全球财务总监，自2018年6月起担任首席会计官。普劳特女士于2018年3月加入公司，在晋升为副总裁之前，曾担任高级董事兼全球财务总监以及执行董事兼全球财务总监。在加入Amicus之前，普劳特女士在NRG能源公司工作了近三年，先是担任家用太阳能部门的主管，然后担任财务报告主管。在加入NRG之前，普劳特女士在毕马威会计师事务所工作了15年，最后9年是在新泽西州生命科学事务所担任审计高级经理。普劳特女士在葛底斯堡学院获得文学士学位，是新泽西州的注册会计师。
Samantha Prout, has served as Vice President and Global Controller since March of 2020 and Principal Accounting Officer since June of 2018. Ms. Prout joined the Company in March of 2018 and held the positions of both Senior Director & Global Controller and Executive Director & Global Controller prior to her promotion to Vice President. Prior to joining Amicus, Ms. Prout spent nearly three years at NRG Energy “NRG”, first as Controller for Home Solar division, then as the Director of Financial Reporting. Prior to joining NRG, Ms. Prout spent over 15 years at KPMG LLP, the final nine as an Audit Senior Manager serving the life science practice in New Jersey. Ms. Prout received a Bachelor of Arts from Gettysburg College and is a certified public accountant in New Jersey.- Samantha Prout自2020年3月起担任副总裁兼全球财务总监，自2018年6月起担任首席会计官。普劳特女士于2018年3月加入公司，在晋升为副总裁之前，曾担任高级董事兼全球财务总监以及执行董事兼全球财务总监。在加入Amicus之前，普劳特女士在NRG能源公司工作了近三年，先是担任家用太阳能部门的主管，然后担任财务报告主管。在加入NRG之前，普劳特女士在毕马威会计师事务所工作了15年，最后9年是在新泽西州生命科学事务所担任审计高级经理。普劳特女士在葛底斯堡学院获得文学士学位，是新泽西州的注册会计师。
- Samantha Prout, has served as Vice President and Global Controller since March of 2020 and Principal Accounting Officer since June of 2018. Ms. Prout joined the Company in March of 2018 and held the positions of both Senior Director & Global Controller and Executive Director & Global Controller prior to her promotion to Vice President. Prior to joining Amicus, Ms. Prout spent nearly three years at NRG Energy “NRG”, first as Controller for Home Solar division, then as the Director of Financial Reporting. Prior to joining NRG, Ms. Prout spent over 15 years at KPMG LLP, the final nine as an Audit Senior Manager serving the life science practice in New Jersey. Ms. Prout received a Bachelor of Arts from Gettysburg College and is a certified public accountant in New Jersey.
- John F. Crowley
John F. Crowley，自2010年2月他为董事长兼首席执行官，自2005年1月起为首席执行官，除了从2011年4月至2011年8月期间出任执行董事长。自2004年8月，他还担任Amicus的董事，除了从2006年9月至2007年3月的期间时，他不是Amicus的职员或董事，而是在美国的海军预备役部队服役。他是Orexigen Therapeutics的总裁兼首席执行官从2003年9月至2004年12月。他Novazyme制药公司的总裁兼首席执行官从2000年3月，直到该公司于2001年9月被Genzyme公司收购；此后，他曾担任 Genzyme Therapeutics的高级副总裁直至2002年12月。他获得乔治城大学的外交学院的外交服务学士学位，圣母大学法学院的法学博士学位，和哈佛商学院的MBA学位。
John F. Crowley has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January 2005 except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr. Crowley has also served as a director of Amicus since August 2004 except for the period from September 2006 to March 2007 when he was in active duty service in the United States Navy Reserve. Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporation (“Genzyme”) in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Currently, Mr. Crowley serves as a member of the Board of Directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Mr. Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School.- John F. Crowley，自2010年2月他为董事长兼首席执行官，自2005年1月起为首席执行官，除了从2011年4月至2011年8月期间出任执行董事长。自2004年8月，他还担任Amicus的董事，除了从2006年9月至2007年3月的期间时，他不是Amicus的职员或董事，而是在美国的海军预备役部队服役。他是Orexigen Therapeutics的总裁兼首席执行官从2003年9月至2004年12月。他Novazyme制药公司的总裁兼首席执行官从2000年3月，直到该公司于2001年9月被Genzyme公司收购；此后，他曾担任 Genzyme Therapeutics的高级副总裁直至2002年12月。他获得乔治城大学的外交学院的外交服务学士学位，圣母大学法学院的法学博士学位，和哈佛商学院的MBA学位。
- John F. Crowley has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January 2005 except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr. Crowley has also served as a director of Amicus since August 2004 except for the period from September 2006 to March 2007 when he was in active duty service in the United States Navy Reserve. Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporation (“Genzyme”) in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Currently, Mr. Crowley serves as a member of the Board of Directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Mr. Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School.
- Bradley L. Campbell
Bradley L. Campbell，自2013年12月，他曾担任首席运营官，自2012年2月为首席商务官。2010年1月至2012年2月他担任业务运营高级副总裁；从2007年5月至2010年1月担任业务规划副总裁，并从2006年4月至2007年5月为业务发展高级总监。他担任Myozyme的庞贝氏症的高级产品经理，后来从2002年至2006年担任Genzyme公司的心血管基因治疗业务总监。他还曾在 Bristol-Myers Squibb的销售和市场营销部门工作，并为 Marakon Associates的企业战略顾问。他获得杜克大学的学士学位和哈佛商学院工商管理硕士学位。
Bradley L. Campbell has served as a member of the Board since June 2018 and as President and Chief Operating Officer since January 2015. Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012 Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010 as Vice President, Business Planning and from April 2006 until May 2007 as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme©- for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for Bristol Myers Squibb and as a business strategy consultant for Marakon Associates. Currently, Mr. Campbell also serves as a director for ARYA Sciences Acquisitions Corp III NASDAQ: ARYA and previously served as a director of Progenics (NASDAQ: PGNX). Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School.- Bradley L. Campbell，自2013年12月，他曾担任首席运营官，自2012年2月为首席商务官。2010年1月至2012年2月他担任业务运营高级副总裁；从2007年5月至2010年1月担任业务规划副总裁，并从2006年4月至2007年5月为业务发展高级总监。他担任Myozyme的庞贝氏症的高级产品经理，后来从2002年至2006年担任Genzyme公司的心血管基因治疗业务总监。他还曾在 Bristol-Myers Squibb的销售和市场营销部门工作，并为 Marakon Associates的企业战略顾问。他获得杜克大学的学士学位和哈佛商学院工商管理硕士学位。
- Bradley L. Campbell has served as a member of the Board since June 2018 and as President and Chief Operating Officer since January 2015. Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012 Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010 as Vice President, Business Planning and from April 2006 until May 2007 as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme©- for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for Bristol Myers Squibb and as a business strategy consultant for Marakon Associates. Currently, Mr. Campbell also serves as a director for ARYA Sciences Acquisitions Corp III NASDAQ: ARYA and previously served as a director of Progenics (NASDAQ: PGNX). Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School.
- Daphne Quimi
Daphne Quimi，自2013年12月她一直担任财务副总裁和财务总监。2010年1月至2013年12月她担任财务总监，并自2007年9月起为会计政策和外部报告的董事。2005年10月至2007年9月 她曾在 Bristol-Myers Squibb公司工作，她担任联营和外部报告的董事。她是在新泽西州注册会计师，管理会计师公会会员。 她获得了蒙茅斯大学会计学士学位和纽约大学斯特恩商学院工商管理硕士学位。
Daphne Quimi, has served as the Company's Chief Financial Officer since January 1 2019. Previously she served as the Company's Senior Vice President, Finance and has been employed with Amicus since September 2007. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A. from the Stern School of Business of New York University. She is a certified public accountant in New Jersey.- Daphne Quimi，自2013年12月她一直担任财务副总裁和财务总监。2010年1月至2013年12月她担任财务总监，并自2007年9月起为会计政策和外部报告的董事。2005年10月至2007年9月 她曾在 Bristol-Myers Squibb公司工作，她担任联营和外部报告的董事。她是在新泽西州注册会计师，管理会计师公会会员。 她获得了蒙茅斯大学会计学士学位和纽约大学斯特恩商学院工商管理硕士学位。
- Daphne Quimi, has served as the Company's Chief Financial Officer since January 1 2019. Previously she served as the Company's Senior Vice President, Finance and has been employed with Amicus since September 2007. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A. from the Stern School of Business of New York University. She is a certified public accountant in New Jersey.
- Hung Do
Hung Do，自2013年12月他担任研发生物学高级副总裁。加入 Amicus前，他为Callidus Biopharma（一家私人持有的生物制品公司，被 Amicus收购）的一个共同创始人和首席科学官。在成立CALLIDUS前，他所领导的早期发现研究破译了其小分子药理伴侣是作用机制。他曾帮助演示ERTs的概念验证，并担任Genzyme公司的第二代Pompe ERT的项目负责人。在Novazyme（被Genzyme收购）他也领导分子生物学，细胞培养和纯化工作，并为提高药物靶向的蛋白质疗法帮助开发了体外蛋白质修饰过程。他拥有得克萨斯大学医学生物化学和遗传学博士学位，是埃默里大学的血液学/肿瘤学博士后。
Hung Do, has served as Chief Science Officer since July 2015. Previously, he served as the Company's Senior Vice President, Discovery Biology since December 2013. Prior to joining Amicus, Dr. Do was a co-founder and Chief Scientific Officer of Callidus Biopharma, Inc. “Callidus”, a privately held biologics company that was acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to demonstrate proof of concept for ERTs and served as the project leader for a second generation Pompe ERT at Genzyme. Dr. Do also led molecular biology, cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme Pharmaceuticals, Inc., which was acquired by Genzyme. Dr. Do holds a Ph.D. in medical biochemistry and genetics from Texas A&M University and was a post-doctoral fellow in Hematology/Oncology at Emory University.- Hung Do，自2013年12月他担任研发生物学高级副总裁。加入 Amicus前，他为Callidus Biopharma（一家私人持有的生物制品公司，被 Amicus收购）的一个共同创始人和首席科学官。在成立CALLIDUS前，他所领导的早期发现研究破译了其小分子药理伴侣是作用机制。他曾帮助演示ERTs的概念验证，并担任Genzyme公司的第二代Pompe ERT的项目负责人。在Novazyme（被Genzyme收购）他也领导分子生物学，细胞培养和纯化工作，并为提高药物靶向的蛋白质疗法帮助开发了体外蛋白质修饰过程。他拥有得克萨斯大学医学生物化学和遗传学博士学位，是埃默里大学的血液学/肿瘤学博士后。
- Hung Do, has served as Chief Science Officer since July 2015. Previously, he served as the Company's Senior Vice President, Discovery Biology since December 2013. Prior to joining Amicus, Dr. Do was a co-founder and Chief Scientific Officer of Callidus Biopharma, Inc. “Callidus”, a privately held biologics company that was acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to demonstrate proof of concept for ERTs and served as the project leader for a second generation Pompe ERT at Genzyme. Dr. Do also led molecular biology, cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme Pharmaceuticals, Inc., which was acquired by Genzyme. Dr. Do holds a Ph.D. in medical biochemistry and genetics from Texas A&M University and was a post-doctoral fellow in Hematology/Oncology at Emory University.